Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
Portfolio Pulse from Benzinga Newsdesk
Nanoviricides reports successful progress in the Phase 1a/1b human clinical trial of NV-CoV-2, its broad-spectrum antiviral drug. The trial, sponsored by Indian collaborator Karveer Meditech, has seen 26 out of 36 volunteers complete the Phase 1a Single-Ascending-Dose study, and 17 out of 36 complete the Phase 1b Multiple-Ascending-Dose study. No adverse events have been reported.
August 21, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanoviricides' NV-CoV-2 clinical trial is progressing successfully, which could potentially boost investor confidence in the company.
The successful progress of the NV-CoV-2 clinical trial indicates that Nanoviricides' product is potentially effective and safe. This could lead to regulatory approval and commercialization, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100